Celsion Corporation (CLSN) Analysts See $-0.31 EPS

February 15, 2018 - By Ellis Scott

 Celsion Corporation (CLSN) Analysts See $ 0.31 EPS

Analysts expect Celsion Corporation (NASDAQ:CLSN) to report $-0.31 EPS on March, 15.They anticipate $1.65 EPS change or 84.18 % from last quarter’s $-1.96 EPS. After having $-0.39 EPS previously, Celsion Corporation’s analysts see -20.51 % EPS growth. The stock increased 2.74% or $0.06 during the last trading session, reaching $2.25. About 146,207 shares traded. Celsion Corporation (NASDAQ:CLSN) has declined 82.71% since February 15, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Celsion Corporation (NASDAQ:CLSN) Ratings Coverage

Among 2 analysts covering Celsion (NASDAQ:CLSN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celsion had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, August 12 by Zacks. The stock of Celsion Corporation (NASDAQ:CLSN) earned “Hold” rating by Maxim Group on Thursday, November 10. Maxim Group maintained the stock with “Buy” rating in Tuesday, January 19 report. The firm earned “Buy” rating on Thursday, October 5 by Maxim Group. Oppenheimer initiated the shares of CLSN in report on Monday, November 20 with “Buy” rating. On Monday, August 7 the stock rating was maintained by Maxim Group with “Hold”. The firm earned “Buy” rating on Friday, August 7 by Cantor Fitzgerald. The stock of Celsion Corporation (NASDAQ:CLSN) has “Hold” rating given on Thursday, June 1 by Maxim Group. The rating was maintained by Maxim Group with “Hold” on Tuesday, August 15.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $36.14 million. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

More important recent Celsion Corporation (NASDAQ:CLSN) news were published by: Globenewswire.com which released: “Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides …” on November 14, 2017, also Globenewswire.com published article titled: “Celsion Corporation Provides Corporate Update and 2018 Outlook”, Globenewswire.com published: “Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer …” on February 12, 2018. More interesting news about Celsion Corporation (NASDAQ:CLSN) was released by: Seekingalpha.com and their article: “Celsion Turns Up The Heat On Cancer” with publication date: November 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.